Immunotherapy combo aims to stop hodgkin lymphoma relapse after transplant
NCT ID NCT03057795
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether two immunotherapy drugs, nivolumab and brentuximab vedotin, can prevent Hodgkin lymphoma from coming back after a stem cell transplant. The study includes 62 patients with high-risk Hodgkin lymphoma that had returned or not responded to prior treatment. The main goal is to see how many patients remain cancer-free 18 months after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab and brentuximab vedotin
What this could lead to
If successful, this combination could help prevent Hodgkin lymphoma from returning after a stem cell transplant, improving long-term survival.
What could go wrong
This is a small, early-phase trial with only 62 participants, so results may not apply to all patients. The drugs can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States